Biota Receives $4.2m R&D Tax Credit

Biota Receives $4.2m R&D Tax Credit 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/07/12 --  In addition to
the disclosure in the 2012 Annual Report, Biota Holdings limited
(ASX: BTA) today announced that it received $4.2m in respect to the
Australian Research and Development tax incentive ("Offset "),
following submission of its 2012 Australian tax return.  
As a result, Biota's cash position increased by $4.2m and will be
recognized as a tax credit in the income statement in the December
quarter financial reports. 
About Biota
 Biota is a leading anti-infective drug development
company based in Melbourne Australia, with key expertise in
respiratory diseases, particularly influenza. Biota developed the
first-in-class neuraminidase inhibitor, zanamivir, subsequently
marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs
include a series of candidate drugs aimed at treatment of respiratory
syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections.
Biota has a well advanced program for human rhinovirus (HRV)
infection with a completed Phase IIb study in asthmatic subjects.  
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza antivirals, of which the lead product lnavir(R),
is marketed in Japan. Biota holds a contract from the US Office of
Biomedical Advanced Research and Development Authority (BARDA) for
the advanced development of laninamivir in the USA.  
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of
companies.
 Inavir(R) is registered to Daiichi Sankyo. 
Investor / Analyst Inquiries
Biota Holdings Limited 
Peter Cook 
T: +61 3 9915 3720 
Damian Lismore 
T: +61 3 9915 3721  
Media Inquiries
Nerida Mossop
Hinton & Associates
T: +61 3 9600 1979 / M: +61 437 361 433
Felicity Williams
Hinton & Associates
T: +61 3 9600 1979 / M: +61 416 770 012 
US Inquiries
Hershel Berry
Blueprint Life Science Group
M: +1 415 505 3749 
 
 
Press spacebar to pause and continue. Press esc to stop.